JB/CALL/COSMO PHARMACEUTICALS/55/0.05/21.03.25 Stock

Warrant

COSXJB

CH1308928675

Market Closed - Swiss Exchange 11:20:00 2024-07-05 am EDT
0.888 CHF +4.96% Intraday chart for JB/CALL/COSMO PHARMACEUTICALS/55/0.05/21.03.25
Current month+9.09%
1 month-4.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.888 +4.96%
24-07-04 0.846 +0.12%
24-07-01 0.845 +3.81%
24-06-28 0.814 -2.16%

Delayed Quote Swiss Exchange

Last update July 05, 2024 at 11:20 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying COSMO PHARMACEUTICALS N.V.
Issuer Bank Julius Bär
COSXJB
ISINCH1308928675
Date issued 2023-12-19
Strike 55 CHF
Maturity 2025-03-21 (257 Days)
Parity 20 : 1
Emission price 0.4 CHF
Emission volume N/A
Settlement les deux
Currency CHF

Technical Indicators

Highest since issue 1.092 CHF
Lowest since issue 0.35 CHF
Delta0.89x
Omega 3.613
Premium0.64x
Gearing4.05x
Moneyness 1.316
Difference Strike -17.4 CHF
Difference Strike %-31.64%
Spread 0.01 CHF
Spread %1.11%
Theoretical value 0.8930
Implied Volatility 30.74 %
Total Loss Probability 19.32 %
Intrinsic value 0.8700
Present value 0.0230
Break even 72.86 CHF
Theta-0x
Vega0.01x
Rho0.01x

Company Profile

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Sector
-
More about the company

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Cosmo Pharmaceuticals N.V.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
74.52 EUR
Average target price
96.33 EUR
Spread / Average Target
+29.26%
Consensus
  1. Stock Market
  2. Warrants
  3. COSXJB Warrant